2022
DOI: 10.1016/s1470-2045(22)00451-x
|View full text |Cite
|
Sign up to set email alerts
|

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 43 publications
(8 citation statements)
references
References 29 publications
0
8
0
Order By: Relevance
“…However, collection of survival data can take as long as 10 years, particularly for earlier-stage disease 1 . Event-free survival (EFS) is currently an accepted surrogate end point for the approval of new neoadjuvant therapies; however, this end point relies heavily on radiographic assessment of tumor recurrence (for example, Response Evaluation Criteria in Solid Tumors (RECIST)), and RECIST has recognized limitations in the context of earlier-stage disease 2 , 3 . Robust metrics that can be measured early in therapy and are associated with survival outcomes are invaluable for informing treatment decisions; these can also facilitate and expedite clinical trial reporting.…”
Section: Mainmentioning
confidence: 99%
“…However, collection of survival data can take as long as 10 years, particularly for earlier-stage disease 1 . Event-free survival (EFS) is currently an accepted surrogate end point for the approval of new neoadjuvant therapies; however, this end point relies heavily on radiographic assessment of tumor recurrence (for example, Response Evaluation Criteria in Solid Tumors (RECIST)), and RECIST has recognized limitations in the context of earlier-stage disease 2 , 3 . Robust metrics that can be measured early in therapy and are associated with survival outcomes are invaluable for informing treatment decisions; these can also facilitate and expedite clinical trial reporting.…”
Section: Mainmentioning
confidence: 99%
“…Second, 2-year EFS was used as a benchmark and surrogate end point for OS. However, recent findings from the IFCT-0302 trial 29 indicated that a majority (66%) of disease relapses in patients with early-stage NSCLC occurred within the first 2 years following surgery. Furthermore, approximately 50% of patients in that trial received either preoperative or postoperative treatments.…”
Section: Discussionmentioning
confidence: 99%
“…IFCT-0302 is another randomized controlled trial, which questioned the role of chest CT scanning instead of asking surveillance intervals in patients with completely resected disease. 29 In this trial, patients underwent imaging every 6 months for 2 years and then annually in both arms. However, this cannot be extrapolated to patients with metastatic disease.…”
Section: Discussionmentioning
confidence: 99%